Recent studies have shown that tau protein antibody 43D (targeting tau protein 6-18) can block the cultivation and diffusion of hyperphosphorylated tau protein in AD mice, which is a potential transformational strategy for the treatment of AD (74–76). This evidence concerns the gene MAPT and Alzheimer disease.